BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $60,543,000 | -2.9% | 139,808 | +16.0% | 0.03% | 0.0% |
| Q4 2021 | $62,349,000 | +13.3% | 120,518 | +6.1% | 0.03% | +3.2% |
| Q3 2021 | $55,052,000 | +9.7% | 113,609 | +2.0% | 0.03% | +10.7% |
| Q2 2021 | $50,164,000 | +24.5% | 111,412 | +5.6% | 0.03% | +21.7% |
| Q1 2021 | $40,304,000 | +17.9% | 105,527 | -2.0% | 0.02% | +9.5% |
| Q4 2020 | $34,197,000 | +30.4% | 107,691 | +1.8% | 0.02% | +10.5% |
| Q3 2020 | $26,219,000 | -3.5% | 105,837 | +2.9% | 0.02% | -9.5% |
| Q2 2020 | $27,164,000 | +40.6% | 102,867 | +0.9% | 0.02% | +16.7% |
| Q1 2020 | $19,326,000 | -16.9% | 101,920 | -3.7% | 0.02% | +5.9% |
| Q4 2019 | $23,243,000 | +10.8% | 105,885 | -1.2% | 0.02% | 0.0% |
| Q3 2019 | $20,975,000 | -4.0% | 107,196 | +2.3% | 0.02% | -5.6% |
| Q2 2019 | $21,847,000 | +2.5% | 104,786 | -2.3% | 0.02% | 0.0% |
| Q1 2019 | $21,304,000 | +30.8% | 107,297 | -4.7% | 0.02% | +12.5% |
| Q4 2018 | $16,289,000 | -28.9% | 112,552 | +0.3% | 0.02% | -20.0% |
| Q3 2018 | $22,901,000 | +31.0% | 112,201 | -5.1% | 0.02% | +17.6% |
| Q2 2018 | $17,486,000 | +29.9% | 118,191 | +32.6% | 0.02% | +30.8% |
| Q1 2018 | $13,460,000 | +25.3% | 89,113 | +7.5% | 0.01% | +18.2% |
| Q4 2017 | $10,740,000 | +5.4% | 82,902 | -1.6% | 0.01% | 0.0% |
| Q3 2017 | $10,185,000 | +11.3% | 84,252 | +8.2% | 0.01% | 0.0% |
| Q2 2017 | $9,151,000 | +13.1% | 77,881 | -2.1% | 0.01% | -8.3% |
| Q1 2017 | $8,089,000 | +22.2% | 79,577 | +23.6% | 0.01% | +33.3% |
| Q4 2016 | $6,622,000 | -11.9% | 64,399 | -6.2% | 0.01% | -18.2% |
| Q3 2016 | $7,519,000 | -17.7% | 68,665 | -15.2% | 0.01% | -21.4% |
| Q2 2016 | $9,134,000 | +18.3% | 80,998 | -0.9% | 0.01% | +16.7% |
| Q1 2016 | $7,722,000 | +17.4% | 81,701 | +11.8% | 0.01% | +9.1% |
| Q4 2015 | $6,578,000 | -6.1% | 73,084 | -3.6% | 0.01% | -21.4% |
| Q3 2015 | $7,007,000 | +67.6% | 75,783 | +78.5% | 0.01% | +75.0% |
| Q2 2015 | $4,182,000 | +22.0% | 42,465 | +24.2% | 0.01% | +14.3% |
| Q1 2015 | $3,429,000 | +9.8% | 34,192 | +1.1% | 0.01% | 0.0% |
| Q4 2014 | $3,124,000 | – | 33,806 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |